COVID-19 is a new respiratory virus that has caused a major global pandemic. There is an urgent need for new treatments for COVID-19 and similar and related viral infections also in the view of potential future pandemics.

SPOR-COV ™, a collaboration between Destiny Pharma and SporeGen Limited is a prophylactic approach that targets the innate immune system with potential to develop protection within a few days of treatment.

The SPOR-COV ™  product consists of a proprietary formulation of Bacillus bacteria that will be administered nasally as a spray. SPOR-COV ™  has already been shown by SporeGen to provide complete (100%) protection in preclinical models of influenza.

SPOR-COV ™  is different to vaccines in that it modulates the innate immune system with the aim of developing viral protection within a few days after dosing. As an “easy to use” first line of defence, it has the potential to reduce COVID-19 and other viral infections rates and transmission significantly. The final SPOR-COV ™  product is planned to be straightforward to produce at both high volumes and at low cost. Additional attributes are that it can be stockpiled almost indefinitely without the need for cold chain refrigeration as it is a very stable product. It could be made available globally as a cost-effective measure in the fight against any new COVID strains and other respiratory viral infections.